Nicaragua Pharmaceuticals and Healthcare Report Q4 2017
BMI View: Despite government efforts to improve healthcare coverage, we continue to view Nicaragua'spharmaceutical market as one of least attractive in the region. Although growing, the size of the overallmarket is among the smallest in Central America and is limited by a largely low-income population with astrong preference for traditional medicines. Furthermore, weak drug regulatory framework and poorhealthcare infrastructure will dampen multinational drugmakers' interest in the country.
Headline Expenditure Projections
Pharmaceuticals: NIO14.5bn (USD508mn) in 2016 to NIO15.5bn (USD520mn) in 2017; +7.4% in localcurrency terms and +2.2% in US dollar terms.
Healthcare: NIO34.7bn (USD1.2bn) in 2016 to NIO39.0bn (USD1.3bn) in 2017; +12.3% in localcurrency terms and +7.0% in US dollar terms.
Latest UpdatesJuly 2017
The launch of a new Russian-Nicaraguan vaccine production venture in the city of Managua will bepostponed for the end of 2017, according to press-service of the Russian Ministry of Health. It has theaim of becoming one of the largest facilities of its kind in Central and Latin America.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook